Citation Impact
Citing Papers
Filgotinib: First Approval
2020
Filgotinib suppresses HIV-1–driven gene transcription by inhibiting HIV-1 splicing and T cell activation
2020
Guidelines on Urolithiasis<footref rid="foot01"><sup>1</sup></footref>
2001 Standout
The Energy Values of Dietary Fibre and Sugar Alcohols for Man
1992
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
2011 StandoutNobel
Gout
2009 Standout
Genetics of Inflammatory Bowel Diseases
2015
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
2006 Standout
Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008
2011 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men
2004
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Crohn's disease
2016 Standout
Gout
2016 Standout
Mechanisms of benzarone and benzbromarone‐induced hepatic toxicity†
2005
Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4
2014 StandoutNobel
Current jakinibs for the treatment of rheumatoid arthritis: a systematic review
2021
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Intake of purine‐rich foods, protein, and dairy products and relationship to serum levels of uric acid: The Third National Health and Nutrition Examination Survey
2005
CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanisms
2009
The epidemiology of Parkinson's disease: risk factors and prevention
2016 Standout
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
2020
British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout
2007
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II
2007 Standout
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Coffee and Health: A Review of Recent Human Research
2006 Standout
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques
2006
Global epidemiology of gout: prevalence, incidence and risk factors
2015 Standout
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016
2019 Standout
The safety of baricitinib in patients with rheumatoid arthritis
2020
Targeting the JAK/STAT pathway in solid tumors
2020
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
2020
The effectiveness of popular, non‐prescription weight loss supplements
1999
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Gout
2021 Standout
Fiber and Prebiotics: Mechanisms and Health Benefits
2013 Standout
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
2021
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
2012 StandoutNobel
Dissolution of Uric Acid Calculi
1984
Works of F. Matzkies being referenced
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
2019
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
2019
The Uricosuric Action of Protein in Man
1980
LB0003 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS NAïVE TO METHOTREXATE THERAPY: FINCH3 PRIMARY OUTCOME RESULTS
2019
[Effect of a fiber-containing dietary formula on metabolism].
1982
SAT0158 EFFICACY AND SAFETY OF FILGOTINIB IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS: FINCH 3 52-WEEK RESULTS
2020
CTLA‐4 lacking the cytoplasmic domain costimulates IL‐2 production in T‐cell hybridomas
2006
Verwertung und Stoffwechselverhalten von Sorbit während parenteraler Langzeitinfusion
1973
THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS
2020
P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
2020
Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study
2012
LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS
2019
The Action of Benzbromarone in Relation to Age, Sex and Accompanying Diseases
1980
THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
2020
The Uricosuric Action of Amino Acids in Man
1977